Practical Application of PARP Inhibitors in Metastatic CRPC

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Related Videos
Yuan Yuan, MD, PhD
Jeffery Zonder, MD
David R. Wise, MD, PhD
Andrew J. Armstrong, MD, MSc
Benjamin V. Stone, MD
Scott Tagawa, MD, MS, FACP
Expert on RCC
Experts on DTC
Experts on DTC
Expert on RCC
Related Content